Start › Rak płuc › Kalifornia › San Francisco
Badania kliniczne dla Rak płuc w mieście San Francisco, CA
22 badań dla Rak płuc szuka uczestników w ośrodkach w mieście San Francisco i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study of ZW251 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekrutacjaFaza 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekrutacjaFaza 3
- Kaiser Permanente-San Francisco, San Francisco
Smoking Cessation CM for Veterans With or at Risk for Cancer
RekrutacjaZapraszamy zdrowych ochotników
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutacja
- Kaiser Permanente-San Francisco, San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekrutacjaFaza 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekrutacjaFaza 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekrutacjaFaza 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekrutacjaFaza 1
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekrutacjaFaza 3
- UCSF Medical Center-Mission Bay, San Francisco
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- California Pacific Medical Center-Pacific Campus, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RekrutacjaFaza 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekrutacjaFaza 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekrutacjaFaza 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekrutacja
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekrutacjaFaza 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RekrutacjaFaza 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekrutacjaFaza 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, San Francisco
Badania dla Rak płuc w innych miastach
- Houston, TX78 badań
- Boston, MA62 badań
- New York City, NY60 badań
- Los Angeles, CA45 badań
- Arlington, VA41 badań
- Washington, DC41 badań
- Chicago, IL41 badań
- Baltimore, MD40 badań
- Nashville, TN40 badań
- St. Louis, MO39 badań
- Columbus, OH37 badań
- Philadelphia, PA36 badań
Inne badania w mieście San Francisco
- Rak prostaty45 badań
- Rak piersi43 badań
- Niedrobnokomórkowy rak płuca36 badań
- Nowotwory (wszystkie typy)35 badań
- Niewydolność serca29 badań
- Nowotwór przerzutowy28 badań
- Czerniak22 badań
- Rak trzustki20 badań
- Rak jajnika19 badań
- Rak jelita grubego i odbytnicy18 badań
- Choroby układu sercowo-naczyniowego18 badań
- Glejak wielopostaciowy17 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.